Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry,Journal of Vascular and Interventional Radiology

当前位置： X-MOL 学术 › J. Vasc. Interv. Radiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry
Journal of Vascular and Interventional Radiology ( IF 2.6 ) Pub Date : 2023-08-30 , DOI: 10.1016/j.jvir.2023.08.039
Hannah C Hund ₁ , Liping Du ₂ , Lea Matsuoka ₃ , Daniel Y Sze ₄ , Andrew S Kennedy ₅ , Jafar Golzarian ₆ , Ripal T Gandhi ₇ , Zachary S Collins ₈ , Daniel B Brown ₉

Affiliation

Purpose

To determine overall survival (OS), best response, and toxicities in patients with hepatocellular carcinoma (HCC) previously treated with chemoembolization (TACE+) or yttrium-90 resin transarterial radioembolization (TARE) compared with those of TACE-naïve (T-N) participants.

Materials and Methods

In this prospective, observational study, 262 adult participants with HCC were divided into TACE+ (n = 93, 35%) or T-N (n = 169, 65%) groups, included from 36 centers in the United States. Overall survival (OS) was assessed using Kaplan-Meier analysis from the date of TARE. Best response at 6 months was evaluated using modified Response Evaluation Criteria in Solid Tumors. Six-month toxicities were reported using Common Terminology Criteria for Adverse Events, version 5.

Results

Median OS for patients in the TACE+ and T-N groups was 22.3 months (95% CI: 17.2 to not reachable) and 21.5 months (95% confidence interval [CI]: 14.9–29.9), respectively (P = .6). Imaging at 6 months ± 2 weeks was available in 156 of 262 (60%) participants. Partial or complete response was seen in 27 of 55 patients (49%) in the TACE+ group and 65 of 101 patients (64%) in the T-N group (P = .2). Six-month toxicities were available in 69 of 93 patients (74%) in the TACE+ group and 135 of 167 patients (81%) in the T-N group. Attributable Grade 3 or greater liver function toxicities were similar between the study groups (all P > .05).

Conclusions

OS and imaging response at 6 months in the TACE+ group was similar to that in the T-N group with similar toxicities. Radioembolization is an acceptable treatment option for patients with HCC previously treated with TACE.

中文翻译：

不可切除性肝脏肿瘤登记中放射 SIR 球中钇 90 经动脉放射栓塞治疗肝细胞癌后既往经动脉化疗栓塞对生存和毒性的影响

目的

旨在确定既往接受过化疗栓塞 (TACE+) 或钇 90 树脂经动脉放射栓塞 (TARE) 治疗的肝细胞癌 (HCC) 患者与未接受过 TACE (TN) 治疗的患者的总生存期 (OS)、最佳反应和毒性。

材料和方法

在这项前瞻性观察性研究中，来自美国 36 个中心的 262 名成年 HCC 参与者被分为 TACE+（n = 93，35%）组或 TN（n = 169，65%）组。从 TARE 之日起使用 Kaplan-Meier 分析评估总生存期 (OS)。使用修改后的实体瘤疗效评估标准评估 6 个月时的最佳疗效。使用不良事件通用术语标准第 5 版报告了六个月的毒性。

结果

TACE+ 组和 TN 组患者的中位 OS 分别为 22.3 个月（95% CI：17.2 至无法达到）和 21.5 个月（95% 置信区间 [CI]：14.9–29.9）（ P = .6）。 262 名参与者中的 156 名 (60%) 进行了 6 个月±2 周的影像学检查。 TACE+ 组 55 名患者中有 27 名 (49%) 出现部分或完全缓解，TN 组 101 名患者中有 65 名 (64%) 出现部分或完全缓解 ( P = .2)。 TACE+ 组 93 名患者中有 69 名（74%）出现六个月毒性，TN 组 167 名患者中有 135 名（81%）出现六个月毒性。研究组之间可归因的 3 级或以上肝功能毒性相似（所有P > .05）。